Clinical & Pharmaceutical Solutions through Analysis
July 29 - 30, 2014
Club Transatlântico, São Paulo
Where Technology and Solutions Meet!
CPSA Brasil 2014
Emerging Models for Drug Development and the Clinical Laboratory: Innovative Technologies and Future Applications
2014 Plenary Speaker
Randall W. Nelson, PhD
Some Thoughts on Biomarker Translation
A search of Pubmed returns in excess of 650,000 publications containing the general term “biomarker”. Restricted to “protein biomarker”, this number reduces to 510,000; and then drastically to 8,000 publications when searching with “biomarker proteomics”. The time spanned by these publications is also significantly different – over three-decades for the general term, but only 10-years regarding proteomics. From these observations, we can conclude that the study of biomarkers is neither novel nor rare, and that proteomics-based investigations are a relatively new addition to the field. Consequently, there has been much focus on the promise of new proteomics-derived biomarkers, accompanied by a flood of new investigators and numerous descriptions of roads, pathways and pipelines for developing new protein biomarkers. To date, however, these efforts have not had a significant impact on the production and mainstream use of new biomarkers/biosignatures of disease. Presented here are some thoughts and observations on overcoming common hurdles encountered in biomarker development, with particular focus on the use of novel, mass spectrometric-based diagnostic assays.